How Is Tysabri-Related PML Monitored? Understanding Risk Factors and Follow-Up Exams

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Pharmaceutical Risks

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance and clinical research have established clear patterns linking certain risk factors—such as JC virus antibody status and duration of therapy—to PML development. This page outlines the key risk factors, recommended monitoring protocols, and what to discuss with your healthcare provider.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the John Cunningham virus (JCV), a common virus that remains latent in most individuals but can reactivate in immunocompromised states. The boxed warning further notes that "risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment. The clinical presentation of PML is variable and often insidious. Patients may develop progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, visual loss, or speech difficulties. The diagnosis is typically confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Because PML can progress rapidly, the prescribing information instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) frequently list neurological symptoms that overlap with early PML, including fatigue (19,150 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), balance disorder (5,621 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the challenge of distinguishing PML from other neurological conditions in patients receiving Tysabri.

Mechanism of PML Development and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4 on lymphocytes, Tysabri prevents immune cells from crossing the blood-brain barrier. This reduces central nervous system inflammation—beneficial for multiple sclerosis—but also impairs immune surveillance against JCV. In immunocompromised individuals, JCV can reactivate and infect oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk increases with longer treatment duration, particularly beyond two years, and in patients who have received prior immunosuppressive therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients in Arizona who have developed PML after Tysabri treatment, legal considerations regarding the statute of limitations are critical. In Arizona, the statute of limitations for personal injury claims generally is two years from the date the injury is discovered or reasonably should have been discovered. For medical malpractice or product liability claims involving Tysabri, the clock may start when the patient is diagnosed with PML or when symptoms become apparent. However, because PML can have a delayed onset after drug exposure, the timeline between the last Tysabri infusion and the appearance of neurological symptoms may be months or even years. This latency period can complicate the determination of when the injury was "discovered." Patients and their families should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances.

Adequacy of Warnings and Legal Recourse

Adequacy of warnings is another key issue. The boxed warning and prescribing information clearly state the increased risk of PML and the need for monitoring. However, some patients may argue that the warnings were insufficient to convey the severity or likelihood of PML, or that healthcare providers failed to adequately monitor for early signs. The TOUCH Prescribing Program, which restricts Tysabri distribution to certified prescribers and infusion centers, is designed to ensure that patients are informed of risks and monitored regularly (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Nonetheless, adverse events continue to be reported, raising questions about whether the program effectively prevents harm. In summary, Tysabri carries a well-documented risk of PML, a devastating brain infection. Patients in Arizona who have been harmed should be aware of the statute of limitations and seek legal advice promptly. The medical evidence supports a causal link between Tysabri and PML, and the risk factors are clearly outlined in the drug's labeling. However, the adequacy of warnings and the timeliness of diagnosis remain areas of concern for affected individuals.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Arizona?

In Arizona, the statute of limitations for personal injury claims generally is two years from the date the injury is discovered or reasonably should have been discovered. For Tysabri-related PML, the clock may start when the patient is diagnosed with PML or when symptoms become apparent. Because PML can have a delayed onset, it is crucial to consult an attorney promptly to assess your specific timeline.

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer duration of therapy (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the drug's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in patients taking Tysabri?

Diagnosis is typically confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Clinical symptoms include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, visual loss, or speech difficulties.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.